Last reviewed · How we verify
GCFLU Quadrivalent Inj. vaccine
GCFLU Quadrivalent Inj. vaccine is a Inactivated influenza vaccine Biologic drug developed by Green Cross Corporation. It is currently in Phase 3 development for Seasonal influenza prevention in adults and children. Also known as: GCFLU Quadrivalent Inj..
GCFLU Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
GCFLU Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | GCFLU Quadrivalent Inj. vaccine |
|---|---|
| Also known as | GCFLU Quadrivalent Inj. |
| Sponsor | Green Cross Corporation |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) virus particles or viral antigens from four influenza strains (typically two A subtypes and two B lineages). Upon injection, these antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that provide protection against infection with matching circulating influenza viruses.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain, redness, or swelling
- Myalgia (muscle pain)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects (PHASE2)
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults (PHASE1)
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age (PHASE3)
- A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GCFLU Quadrivalent Inj. vaccine CI brief — competitive landscape report
- GCFLU Quadrivalent Inj. vaccine updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about GCFLU Quadrivalent Inj. vaccine
What is GCFLU Quadrivalent Inj. vaccine?
How does GCFLU Quadrivalent Inj. vaccine work?
What is GCFLU Quadrivalent Inj. vaccine used for?
Who makes GCFLU Quadrivalent Inj. vaccine?
Is GCFLU Quadrivalent Inj. vaccine also known as anything else?
What drug class is GCFLU Quadrivalent Inj. vaccine in?
What development phase is GCFLU Quadrivalent Inj. vaccine in?
What are the side effects of GCFLU Quadrivalent Inj. vaccine?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: Green Cross Corporation — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Also known as: GCFLU Quadrivalent Inj.
- Compare: GCFLU Quadrivalent Inj. vaccine vs similar drugs
- Pricing: GCFLU Quadrivalent Inj. vaccine cost, discount & access